サイト内検索

登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録

連絡先

TEL．03-5812-5270
FAX．03-3831-0495
E-mail：info@spi-information.com

関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。

Specialty Pharmaceutical Industry - 2011 Yearbook

スペシャリティファーマ産業年鑑 − 2011年度版

レポート概要

本レポートは、2017年までのスペシャリティファーマの売上および価格予測に関する重要な見識を提供し、治療薬の年間コスト(ACT) や収益など、8つのニッチ適応症（ヒト免疫不全ウイルス(HIV)/ 後天性免疫不全症候群(AIDS)、加齢黄斑変性疾患、注意欠陥多動性障害(ADHD)、アルツハイマー病、結腸直腸癌、関節リウマチ、てんかん、および緑内障）の詳細な治療薬分析を提供します。また、アメリカ、ヨーロッパ上位5カ国、および日本におけるこれら疾病の治療薬の地理的分布や、2017年までのスペシャリティファーマ研究開発(R&D)パイプラインと潜在的な将来のブロックバスターに関する見識を提供します。さらに、2017年までの上記8治療薬適応症の市場予測と治療薬の使用パターンを解説し、スペシャリティファーマ産業における合併買収(M&A)、ライセンス契約、および共同開発取引に関する主要動向を分析します。

■調査範囲

  • スペシャリティファーマ市場に対する2001〜2009年の年間市場データと2017年までの予測を提供します。
  • 世界の専門製薬市場における8つの主要な適応症（ヒト免疫不全ウイルス(HIV)/ 後天性免疫不全症候群(AIDS)、加齢黄斑変性疾患、注意欠陥多動性障害(ADHD)、アルツハイマー病、結腸直腸癌、関節リウマチ、てんかん、および緑内障）に対する市場分析を提供します。
  • 世界の主要地域（アメリカ、イギリス、ドイツ、フランス、イタリア、スペイン、および日本）における専門製薬市場に関するデータおよび分析を提供します。
  • 市場規模、市場シェア、治療薬の年間コスト、売上高、および患者群、治療を求める患者群、診断群、および処方群などの治療薬の使用パターンなど、地理的展望および治療薬の展望に関する市場データを提供します。
  • スペシャリティファーマ市場で2004〜2010年に起こった重要なM&Aとライセンス契約を提供します。

レポート詳細

調査項目

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Specialty Pharmaceutical Market- 2011 Yearbook: Introduction
2.1 Scope
2.2 GBI Research Report Guidance

3 Specialty Pharmaceutical Market- 2011 Yearbook: HIV Therapeutics Market
3.1 Disease Overview
3.2 Market Overview
3.3 Global HIV Therapeutics Market: Market Characterization
3.3.1 Market Forecasts
3.3.2 Annual Cost of Therapy
3.3.3 Usage Patterns
3.3.4 Geographical Distribution
3.4 HIV Therapeutics Market: Drivers and Restraints
3.4.1 Market Drivers
3.4.2 Market Restraints

4 Specialty Pharmaceutical Market- 2011 Year Book: Age Related Macular Degenerative Disorder
4.1 Disease Overview
4.2 Market Overview
4.3 Age Related Macular Degenerative Disorder: Market Characterization
4.3.1 Market Forecasts
4.3.2 Geographical Distribution
4.3.3 Annual Cost of Therapy
4.3.4 Usage Patterns
4.4 Age Related Macular Degenerative Disorder: Drivers and Restraints
4.4.1 Market Drivers
4.4.2 Market Restraints

5 Specialty Pharmaceutical Market- 2011 Yearbook: Attention Deficit Hyperactive Disorder (ADHD)
5.1 Introduction
5.2 Attention Deficit Hyperactive Disorder: Market Characterization
5.2.1 Market Forecasts
5.2.2 Geographical Distribution
5.2.3 Annual Cost of Therapy
5.2.4 Usage Patterns
5.3 Attention Deficit Hyperactive Disorder Market: Drivers and Restraints
5.3.1 Market Drivers
5.3.2 Market Restraints

6 Specialty Pharmaceutical Market- 2011 Yearbook: Alzheimer’s Disease
6.1 Introduction
6.2 Alzheimer’s disease: Market Characterization
6.2.1 Market Forecasts
6.2.2 Geographical Distribution
6.2.3 Annual Cost of Therapy
6.2.4 Usage Patterns
6.3 Alzheimer’s Disease Market: Drivers and Restraints
6.4 Market Drivers
6.5 Market Restraints

7 Specialty Pharmaceutical Market- 2011 Yearbook: Colorectal Cancer
7.1 Introduction
7.2 Colorectal Cancer: Market Characterization
7.2.1 Market Forecasts
7.2.2 Geographical Distribution
7.2.3 Annual Cost of Therapy
7.2.4 Usage Patterns
7.3 Colorectal Cancer Market: Drivers and Restraints
7.3.1 Market Drivers
7.3.2 Market Restraints

8 Specialty Pharmaceutical Market- 2011 Yearbook: Rheumatoid Arthritis
8.1 Introduction
8.2 Rheumatoid Arthritis: Market Characterization
8.2.1 Market Forecasts
8.2.2 Annual Cost of Therapy
8.2.3 Treatment Usage Patterns
8.2.4 Geographical Distribution
8.3 Rheumatoid Arthritis Market: Drivers and Restraints
8.3.1 Market Drivers
8.3.2 Market Restraints

9 Specialty Pharmaceutical Market- 2011 Yearbook: Epilepsy
9.1 Introduction
9.2 Epilepsy: Market Characterization
9.2.1 Market Forecasts
9.2.2 Geographical Distribution
9.2.3 Annual Cost of Therapy
9.2.4 Usage Patterns
9.3 Epilepsy Market: Drivers and Restraints
9.3.1 Market Drivers
9.3.2 Market Restraints

10 Specialty Pharmaceutical Market- 2011 Yearbook: Glaucoma
10.1 Introduction
10.2 Glaucoma: Market Characterization
10.2.1 Market Forecasts
10.2.2 Geographical Distribution
10.2.3 Annual Cost of Therapy
10.2.4 Usage Patterns
10.3 Glaucoma Market: Drivers and Restraints
10.3.1 Drivers of the Glaucoma Market
10.3.2 Barriers for the Glaucoma Market

11 Specialty Pharmaceutical Market- 2011Yearbook: Pipeline Analysis
11.1 Specialty Pharmaceutical Pipeline: HIV market
11.2 Molecule Profile for Promising Drugs under Clinical Development: HIV
11.2.1 Rilpivirine hydrochloride (TMC278)
11.2.2 Elvitegravir
11.2.3 Elvitegravir/GS-9350/Emtricitabine/Tenofovir (Quad)
11.2.4 Racivir
11.2.5 Apricitabine (ATC)
11.2.6 Tesamorelin
11.3 Specialty Pharmaceutical Pipeline: Age Related Macular Degeneration
11.4 Molecule Profile for Promising Drugs under Clinical Development: Age Related Macular Degeneration
11.4.1 VEGF Trap-Eye
11.5 Specialty Pharmaceutical Pipeline: Attention Deficit Hyperactive Disorder
11.6 Molecule Profile for Promising Drugs under Clinical Development: Attention Deficit Hyperactive Disorder
11.6.1 ABT-894 (Sofinicline)
11.6.2 Eltoprazine
11.6.3 AZD3480 (TC-1734) (Isopronicline)
11.7 Specialty Pharmaceutical Pipeline: Alzheimer’s Disease
11.8 Molecular Profile for the Promising Drugs under Clinical Development: Alzheimer’s Disease
11.8.1 Bapineuzumab
11.8.2 Gammagard
11.8.3 Dimebon
11.8.4 Rember (Trx0014) (methylthionium chloride)
11.9 Specialty Pharmaceutical Pipeline: Colorectal Cancer
11.10 Molecule Profile for Promising Drugs under Clinical Development: Colorectal Cancer
11.10.1 Aflibercept
11.10.2 Brivanib
11.10.3 OncoVAX
11.10.4 TroVax
11.10.5 KRX-0401 (Perifosine)
11.11 Specialty Pharmaceutical Pipeline: Rheumatoid Arthritis
11.12 Profiles for Promising Drugs under Clinical Development: Rheumatoid Arthritis
11.12.1 T-614 (iguratimod)
11.12.2 CP-690550
11.12.3 Arzerra (HuMax-CD20 /Ofatumumab)
11.12.4 VX-509
11.13 Specialty Pharmaceutical Pipeline: Epilepsy
11.14 Molecule Profile for Promising Drugs under Clinical Development: Epilepsy
11.14.1 Stedesa (Eslicarbazepine Acetate)
11.14.2 Comfyde (Carisbamate)
11.14.3 Retigabine
11.14.4 Brivaracetam
11.14.5 Ganaxolone
11.14.6 E2007 (Perampanel)
11.15 Specialty Pharmaceutical Pipeline: Glaucoma
11.16 Molecule Profile for Promising Drugs under Clinical Development: Glaucoma
11.16.1 Tafluprost (Saflutan)
11.16.2 NCX-116 (Formerly PF-03187207)

12 Specialty Pharmaceutical Market- 2011 Yearbook: Strategic Consolidations
12.1 Mergers and Acquisitions
12.1.1 Pfizer
12.1.2 F. Hoffmann-La Roche
12.1.3 GlaxoSmithKline
12.2 Licensing Deals
12.2.1 Pfizer
12.2.2 F. Hoffmann-La Roche
12.2.3 GlaxoSmithKline
12.3 Co-Development Deals
12.3.1 Pfizer
12.3.2 F. Hoffmann-La Roche
12.3.3 GlaxoSmithKline

13 Specialty Pharmaceutical Market- 2011 Yearbook: Appendix
13.1 Market Definitions
13.2 Abbreviations
13.3 Research Methodology
13.3.1 Coverage
13.3.2 Secondary Research
13.3.3 Primary Research
13.3.4 Forecasts
13.3.5 Expert Panel Validation
13.4 Contact Us
13.5 Disclaimer
13.6 Sources

1.1 List of Tables
Table 1: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Revenue ($m), 2001-2009
Table 2: Specialty Pharmaceutical Market, HIV Market, Global, Revenue ($m), 2009-2017
Table 3: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 4: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2017
Table 5: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2001-2009
Table 6: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2001-2009
Table 7: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), by countries, 2001-2009
Table 8: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), by countries, 2009-2017
Table 9: HIV Therapeutics Market, Global, Key Drugs Going Off Patent, 2008-2016
Table 10: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($m), 2001-2009
Table 11: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($m), 2009-2017
Table 12: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues , 2001-2009
Table 13: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues, 2010-2017
Table 14: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2001-2009
Table 15: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2009-2017
Table 16: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2001-2009
Table 17: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2009-2017
Table 18: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($m), 2001-2009
Table 19: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($m), 2009-2017
Table 20: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($m), 2001-2009
Table 21: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($m), 2009-2017
Table 22: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2001-2009
Table 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2009-2017
Table 24: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2001-2009
Table 25: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2009-2017
Table 26: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Revenue ($m), 2001-2009
Table 27: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Revenue ($m), 2009-2017
Table 28: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Geographical Distribution of Revenues ($m), 2001-2009
Table 29: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Geographical Distribution of Revenues ($m), 2009-2017
Table 30: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Annual Cost of Therapy ($), 2001-2009
Table 31: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Annual Cost of Therapy ($), 2009-2017
Table 32: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Usage Patterns, 2001-2009
Table 33: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Usage Patterns, 2009-2017
Table 34: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($m), 2001-2009
Table 35: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($m), 2009-2017
Table 36: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Geographical Distribution of Revenues ($m), 2001-2009
Table 37: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Geographical Distribution of Revenues ($m), 2009-2017
Table 38: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2001-2009
Table 39: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2009-2017
Table 40: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2001-2009
Table 41: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2009-2017
Table 42: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($m), 2001-2009
Table 43: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($m), 2009-2017
Table 44: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2001-2009
Table 45: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2009-2017
Table 46: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2001-2009
Table 47: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2009-2017
Table 48: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($m), 2001-2009
Table 49: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($m), 2009-2017
Table 50: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($m), 2001-2009
Table 51: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($m), 2009-2017
Table 52: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2001-2009
Table 53: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2009-2017
Table 54: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2001-2009
Table 55: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2009-2017
Table 56: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2001-2009
Table 57: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2009-2017
Table 58: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($m), 2001-2009
Table 59: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($m), 2009-2017
Table 60: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2001-2009
Table 61: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($m), 2009-2017
Table 62: Specialty Pharmaceutical Market, Glaucoma, Global, Annual Cost of Therapy ($), 2001-2009
Table 63: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2009-2017
Table 64: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2001-2009
Table 65: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2009-2017
Table 66: Specialty Pharmaceutical Market, M&A, Pfizer, 2004 to 2010
Table 67: Specialty Pharmaceutical Market, M&A, F. Hoffmann-La Roche, 2004 to 2010
Table 68: Specialty Pharmaceutical Market, M&A, GlaxoSmithKline, 2004 to 2010
Table 69: Specialty Pharmaceutical Market, Licensing Deals, Pfizer, 2004 to 2010
Table 70: Specialty Pharmaceutical Market, Licensing Deals , F. Hoffmann-La Roche, 2004 to 2010
Table 71: Specialty Pharmaceutical Market, Licensing Deals, GlaxoSmithKline, 2004 to 2010
Table 72: Specialty Pharmaceutical Market, Co-development Deals, Pfizer, 2004-2010
Table 73: Specialty Pharmaceutical Market, Co-development Deals, F. Hoffmann-La Roche, 2004-2010
Table 74: Specialty Pharmaceutical Market, Co-development Deals, GlaxoSmithKline, 2004-2010

1.2 List of Figures
Figure 1: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Market Size ($m), 2001-2017
Figure 2: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2017
Figure 3: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Usage Patterns, 2000-2016
Figure 4: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Diseased Population, 2001-2017
Figure 5: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Treatment Seeking Population, 2001-2017
Figure 6: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Diagnosis Population, 2000-2016
Figure 7: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Prescription Population, 2000-2016
Figure 8: Specialty Pharmaceutical Market, HIV Therapeutics Market, Global, Revenue ($m), 2001-2017
Figure 9: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Revenue ($bn), 2001-2017
Figure 10: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Geographical Distribution of Revenues ($bn), 2001-2017
Figure 11: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Annual Cost of Therapy ($), 2001-2017
Figure 12: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Usage Patterns, 2000-2017
Figure 13: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Diseased Population, 2001-2017
Figure 14: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Treatment Seeking Population, 2001-2017
Figure 15: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Diagnosis Population, 2001-2017
Figure 16: Specialty Pharmaceutical Market, Age Related Macular Degenerative Disorder, Global, Prescription Population, 2001-2017
Figure 17: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Revenue ($bn), 2001-2017
Figure 18: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Geographical Distribution of Revenues ($bn), 2001-2017
Figure 19: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Annual Cost of Therapy ($), 2001-2017
Figure 20: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Usage Patterns, 2001-2017
Figure 21: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Diseased Population, 2001-2017
Figure 22: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Treatment Seeking Population, 2001-2017
Figure 23: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Diagnosis Population, 2001-2017
Figure 24: Specialty Pharmaceutical Market, Attention Deficit Hyperactive Disorder, Global, Prescription Population, 2001-2017
Figure 25: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Revenue ($bn), 2001-2017
Figure 26: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Geographical Distribution of Revenues ($bn), 2001-2017
Figure 27: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Annual Cost of Therapy ($), 2001-2017
Figure 28: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Usage Patterns, 2001-2017
Figure 29: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Diseased Population, 2001-2017
Figure 30: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Treatment Seeking Population, 2001-2017
Figure 31: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Diagnosis Population, 2001-2017
Figure 32: Specialty Pharmaceutical Market, Alzheimer’s Disease, Global, Prescription Population, 2001-2017
Figure 33: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Revenue ($bn), 2001-2017
Figure 34: Specialty Pharmaceutical Market Colorectal Cancer, Global, Geographical Distribution of Revenues ($bn), 2001-2017
Figure 35: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Annual Cost of Therapy ($), 2001-2017
Figure 36: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Usage Patterns, 2001-2017
Figure 37: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Diseased Population, 2001-2017
Figure 38: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Treatment Seeking Population, 2001-2017
Figure 39: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Diagnosis Population, 2001-2017
Figure 40: Specialty Pharmaceutical Market, Colorectal Cancer, Global, Prescription Population, 2001-2017
Figure 41: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Revenue ($bn), 2001-2017
Figure 42: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Annual Cost of Therapy ($), 2001-2017
Figure 43: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Usage Patterns, 2001-2017
Figure 44: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Diseased Population, 2001-2017
Figure 45: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Treatment Seeking Population, 2001-2017
Figure 46: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Diagnosis Population, 2001-2017
Figure 47: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Prescription Population, 2001-2017
Figure 48: Specialty Pharmaceutical Market, Rheumatoid Arthritis, Global, Geographical Distribution of Revenues ($bn), 2001-2017
Figure 49: Specialty Pharmaceutical Market, Epilepsy, Global, Revenue ($bn), 2001-2017
Figure 50: Specialty Pharmaceutical Market, Epilepsy, Global, Geographical Distribution of Revenues ($bn), 2001-2017
Figure 51: Specialty Pharmaceutical Market, Epilepsy, Global, Annual Cost of Therapy ($), 2001-2017
Figure 52: Specialty Pharmaceutical Market, Epilepsy, Global, Usage Patterns, 2001-2017
Figure 53: Specialty Pharmaceutical Market, Epilepsy, Global, Diseased Population, 2001-2017
Figure 54: Specialty Pharmaceutical Market, Epilepsy, Global, Treatment Seeking Population, 2001-2017
Figure 55: Specialty Pharmaceutical Market, , Epilepsy, Global, Diagnosis Population, 2001-2017
Figure 56: Specialty Pharmaceutical Market, Epilepsy, Global, Prescription Population, 2001-2017
Figure 57: Specialty Pharmaceutical Market, Glaucoma, Global, Revenue ($bn), 2001-2017
Figure 58: Specialty Pharmaceutical Market, Glaucoma, Global, Geographical Distribution of Revenues ($bn), 2001-2017
Figure 59: Specialty Pharmaceutical Market, Glaucoma, Global, Annual Cost of Therapy ($), 2001-2017
Figure 60: Specialty Pharmaceutical Market, Glaucoma, Global, Usage Patterns, 2001-2017
Figure 61: Specialty Pharmaceutical Market, Glaucoma, Global, Diseased Population, 2001-2017
Figure 62: Specialty Pharmaceutical Market, Glaucoma, Global, Treatment Seeking Population, 2001-2017
Figure 63: Specialty Pharmaceutical Market, Glaucoma, Global, Diagnosis Population, 2001-2017
Figure 64: Specialty Pharmaceutical Market, Glaucoma, Global, Prescription Population, 2001-2017
Figure 65: Specialty Pharmaceutical Market, Pipeline, Indication, 2010
Figure 66: Specialty Pharmaceutical Market, Pipeline, Phase Analysis, 2010
Figure 67: Specialty Pharmaceutical Market, Pipeline, By Indication, 2010
Figure 68: Specialty Pharmaceutical Market, Pipeline, HIV, 2010
Figure 69: Specialty Pharmaceutical Market, Pipeline, Age Related Macular Degeneration, 2010
Figure 70: Specialty Pharmaceutical Market, Pipeline Attention Deficit Hyperactive Disorder, 2010
Figure 71: Specialty Pharmaceutical Market, Pipeline, Alzheimer’s Disease, 2010
Figure 72: Specialty Pharmaceutical Market, Pipeline, Colorectal Cancer, 2010
Figure 73: Specialty Pharmaceutical Market, Pipeline, Rheumatoid Arthritis, 2010
Figure 74: Specialty Pharmaceutical Market, Pipeline, Epilepsy, 2010
Figure 75: Specialty Pharmaceutical Market, Pipeline, Glaucoma, 2010
Figure 76: Specialty Pharmaceutical Market, M&A, Year on Year, 2004 to 2010
Figure 77: Specialty Pharmaceutical Market, M&A, By Indication, 2004 to 2010
Figure 78: Specialty Pharmaceutical Market, M&A, Deal Type, 2004 to 2010
Figure 79: Specialty Pharmaceutical Market, Licensing Deals, Year on Year, 2004 to 2010
Figure 80: Specialty Pharmaceutical Market, Licensing Deals, By Indication, 2004 to 2010
Figure 81: Specialty Pharmaceutical Market, Co-development Deals, Year on Year, 2004 to 2010
Figure 82: Specialty Pharmaceutical Market, Co-development Deals, By Indication, 2004 to 2010
Figure 83: GBI Research Market Forecasting Model

発刊日

2011/05/24

体裁

PDF / 168ページ

販売価格

3,500USD

発行

GBI Research

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

医薬品産業（医療制度、医療観光など）

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる

PAGE